Should You Buy Alvotech SA (ALVO) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/28
ALVO is not a good buy right now for a beginner long-term investor who is impatient and wants to deploy capital immediately. The stock is still digesting meaningful FDA/manufacturing uncertainty (CRL risk spillover to other launches) and fresh legal overhang, while the price is already pushing into near-term resistance with an overbought short-term RSI. I would HOLD/avoid new buying at current levels and only consider re-entering after clearer FDA remediation/approval visibility.
Technical Analysis
Pre-market price is ~5.35 (+0.75%), sitting near first resistance (R1 ~5.362) and below R2 (~5.539). Momentum is improving: MACD histogram is positive (0.0806) and expanding, suggesting a short-term upswing. However, RSI(6) is ~73.5 (effectively overbought/extended), which often coincides with near-term pullback risk—especially when price is testing resistance. Moving averages are converging, implying the trend is not firmly established for a durable long-term uptrend yet. Key levels: support S1 ~4.789 (then S2 ~4.612); pivot ~5.076. With no proprietary buy signals and price near resistance, the immediate risk/reward is not attractive for an impatient long-term entry.
